You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. EVOTEC SE - ADR

Evotec SE - ADR XNAS: EVO

Evotec SE - ADR Live Share Price Today, Share Analysis and Chart

Weak Stock
Download real time

3.31 -0.01 (-0.30%)

58.52% Fall from 52W High

22,930 XNAS Volume

XNAS 28 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Evotec SE - ADR Key Metrics

Default

Market Capitalization

Below industry Median
1,175.4

PE TTM

Negative PE TTM
-6.4

PEG TTM

Below industry Median
0.1

Price to Book

Below industry Median
1.1

Institutional holding current Qtr %

Low in industry
6.7

Revenue Growth Qtr YoY %

Negative Revenue Growth Qtr YoY %
-5.8

Operating Revenue growth TTM %

Negative Operating Revenue growth TTM %
-5.3

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-1.7

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-80.4

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-17.7

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-12.7

Piotroski Score

High in industry
3

Rel Perf vs Sector quarter%

-31.5

ROE Annual %

Negative ROE Annual %
-7.3

RoA Annual %

Negative RoA Annual %
-3.7
All financials are in EUR Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
22.2 / 100
Valuation Score
Expensive Valuation
26.7 / 100
Momentum Score
Technically Bearish
33.8 / 100
Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
7
1Yr Price target upside is 114%
5 analysts

Check P/E Buy Sell Zone

This stock has negative PE


Evotec SE - ADR Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '26750100012501500Actual RevenueAvg. Estimate
Hit

Evotec SE - ADR's Revenue was higher than average estimate 2 times in past 2 years

EPS forecast

Current EPS
-0.3
Avg. Estimate
-0.8
Low Estimate
-1
High Estimate
-0.3
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 200.0% in FY24

Consensus Recommendation

5 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Sell3Buy1Strong Buy

The consensus recommendation from 5 analysts for Evotec SE - ADR is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Evotec SE - ADR Stock Analysis

Evotec SE - ADR stock analysis with key metrics, changes, and trends.

Evotec SE - ADR MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$781.43 M4.8%negative

Annual Revenue fell 4.8%, in the last year to $781.43 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit$83.91 M11.65%positive

Annual Net Profit rose 11.65% in the last year to $83.91 M. Its sector's average net profit growth for the last fiscal year was -32.42%.

Price to Earning Ratio-6.35-negative

Price to Earning Ratio is -6.35, which is negative.

Stock Price$3.31-57.73%negative

Stock Price fell 57.73% and underperformed its sector by 63.4% in the past year.

Quarterly Revenue$184.89 M5.8%negative

Quarterly Revenue fell 5.8% YoY to $184.89 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$39.63 M1.74%negative

Quarterly Net profit fell 1.74% YoY to $39.63 M. Its sector's average net profit growth YoY for the quarter was -47.39%.

Debt to Equity Ratio0.56-positive

Debt to Equity Ratio of 0.56 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-7.27 %-7.27%negative

Return on Equity(ROE) for the last financial year was -7.27%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding3.60 %3.13%positive

Mutual Fund Holding increased by 3.13% in the last quarter to 3.6.

Interest Coverage Ratio-5.87-negative

Interest Coverage Ratio is -5.87, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding6.67 %0.28%positive

Institutional Holding increased by 0.28% in the last quarter to 6.67.

VIEW LESS


Loading data..

Evotec SE - ADR - Company Profile

What does Evotec SE - ADR do?

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE - ADR Management structure

All Gross Remunerations are in USD
Dr. Werner Lanthaler, PhD
Member of the Management Board
-
2023
Gross Remuneration
Year
Dr. Cord Dohrmann, PhD
Chief Scientific Officer and Member of the Management Board
-
2023
Gross Remuneration
Year
Dr. Craig Johnstone
Chief Operating Officer and Member of the Management Board
-
2023
Gross Remuneration
Year
Ms. Laetitia Rouxel
Chief Financial Officer and Member of the Management Board
-
2023
Gross Remuneration
Year
Dr. Matthias Evers
Chief Business Officer and Member of the Management Board
-
2023
Gross Remuneration
Year
Mr. Christian Wojczewski, PhD
Chief Executive Officer and Member of the Management Board
-
2023
Gross Remuneration
Year

Evotec SE - ADR Board of directors

All Gross Remunerations are in USD
Mr. Wesley P. Wheeler
Member of the Supervisory Board
-
2023
Gross Remuneration
Year
Dr. Mario Polywka
Member of the Supervisory Board
-
2023
Gross Remuneration
Year
Mr. Roland Sackers
Vice Chairman of the Supervisory Board
-
2023
Gross Remuneration
Year
Dr. Elaine Sullivan
Member of the Supervisory Board
-
2023
Gross Remuneration
Year
Mr. Duncan McHale
Member of the Supervisory Board
-
2023
Gross Remuneration
Year
Professor Dr. Iris Low-Friedrich
Chairman of the Supervisory Board
-
2023
Gross Remuneration
Year

Evotec SE - ADR FAQ

How is Evotec SE - ADR today?
Evotec SE - ADR today is trading in the red, and is down by -0.30% at 3.31.
Evotec SE - ADR is currently trading down -0.30% on an intraday basis. In the past week the stock fell -5.70%. stock has been down -26.61% in the past quarter and fell -57.73% in the past year. You can view this in the overview section.